Clinical trials: Polio Immunization
Tetanus, Diphtheria
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants
Primary objective: To demonstrate the non-inferiority in terms of seroprotection rates (Hib antigen (PRP), Diphtheria, Tetanus, and Pertussis antigens (PT and FHA), and polio types 1, 2 and 3 antigens) of investigational arm…
- Conditions
- Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Trial name
- NCT02274285
- Testing
- DTaP-IPV/Hib Combined vaccine, DTaP-IPV vaccine and Hib vaccine
- Where
- 12 sites in Japan
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Older
Primary objective: To demonstrate that 3 doses of a vaccine containing Td-IPV valences administered in a 0, 1 and 6-month schedule induce an acceptable immune response in terms of seroprotection rates (SPR) against diphtheria…
- Conditions
- Diphtheria, Tetanus, Poliomyelitis, Pertussis
- Trial name
- NCT01287949
- Testing
- Diphtheria, tetanus, polio and pertussis vaccination
- Where
- 12 sites in France, Germany
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease
This is a randomized cross-sectional study of the Swedish population. Blood samples will be collected from a subpopulation in order to estimate the age specific sero-prevalence of the Swedish population for diseases included in…
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- Sero 2007 (NCT00932269)
- Where
- Sweden
- Volunteers
- 5,400 people, healthy volunteers welcome
- Sponsor
- Swedish Institute for Infectious Disease Control
Poliomyelitis
Immunogenicity nOPV2 With and Without bOPV
This is an open-label randomized clinical trial that will compare immune responses among infants who receive either novel monovalent oral poliovirus vaccine type 2 (nOPV2) alone, bivalent oral poliovirus vaccine (bOPV) alone, or…
- Trial name
- NCT04579510
- Testing
- Novel monovalent oral poliovirus vaccine type 2 (nOPV2), Bivalent oral poliovirus vaccine (bOPV)
- Where
- Bangladesh
- Volunteers
- 795 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Poliomyelitis
Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT
This is a single site, phase 1 study of dmLT as a mucosal adjuvant to control fecal viral shedding when used in combination with intradermally administered fractional dose trivalent IPV (fIPV).
- Trial name
- NCT05327426
- Testing
- Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT), Intradermal fractional dose inactivated polio vaccine (fIPV), Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Allogeneic Haematopoietic Stem Cell Transplantation
Vaccination of Children Following Allogeneic Stem Cell Transplantation
The purpose of this study is to determine the immunogenicity and tolerability of the DTaP-IPV-HBV/Hib combination vaccine Infanrix hexa and the heptavalent pneumococcal conjugate vaccine Prevenar in pediatric recipients of…
- Trial name
- NCT00169728
- Testing
- DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa, heptavalent pneumococcal conjugate vaccine, Prevenar
- Where
- 11 sites in Germany
- Volunteers
- 53 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Poliomyelitis
Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama
The purpose of this clinical trial is to assess the safety and tolerability (primary objective), immunogenicity (primary and secondary objectives), fecal shedding of vaccine viruses (secondary objective) and the potential for…
- Trial name
- NCT05654467
- Testing
- Novel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3), Sabin Monovalent Oral Poliomyelitis Vaccine Type 3 (mOPV3)
- Where
- 3 sites in Panama
- Volunteers
- 1,532 people, healthy volunteers welcome
- Sponsor
- PATH
Poliomyelitis
The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains
The purpose of this study is to evaluate the safety and the immunogenicity of Inactivated Poliomyelitis Vaccine made from Sabin Strains by different does.
- Trial name
- IPV (NCT01048190)
- Testing
- Inactivated Poliomyelitis Vaccine (Sabin strains)
- Where
- China
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Adverse Event Following Immunisation
A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children
Sabin 2 will be withdrawn from routine use globally from April 2016 as per the SAGE recommendations at the time of writing this protocol.
- Trial name
- M2-ABMG (NCT02521974)
- Testing
- SABIN monovalent OPV2
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation
Tuberculosis, Polio
Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan
Routine childhood immunization (RCI) in Pakistan is well below the recommended coverage of 90% with rates as low as 16% in certain regions (Pakistan DHS 2012-3).
- Conditions
- Tuberculosis, Polio, Diphtheria, Pertussis
- Trial name
- NCT03341195
- Testing
- SMS messages and automated calls
- Volunteers
- 3,850 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Poliomyelitis
Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly
The purpose of this study is to investigate the use of a fourth fractional booster dose of sanofi pasteur's IMOVAX Polio injected intradermally (using the Mantoux technique) as booster dose between 15 to 18 months of age, in…
- Trial name
- NCT00885157
- Testing
- Inactivated types 1, 2, and 3 poliovirus, D antigens
- Where
- Philippines
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China
The study will assess the safety of Pentaxim® vaccine as a three-dose primary vaccination at 2, 3, and 4 months of age in order to meet the regulatory requirements for the license renewal as for any other product registered in…
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- NCT01491087
- Testing
- DTacP IPV//PRP~T combined vaccine: PENTAXIM®
- Where
- 3 sites in China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acellular Pertussis, Poliomyelitis
Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults
This study will evaluate the persistence of immune response against diphtheria, tetanus, pertussis and poliomyelitis in healthy adults, 10 years after a booster dose, and also assess the immunogenicity and safety of another…
- Conditions
- Acellular Pertussis, Poliomyelitis, Diphtheria, Tetanus
- Trial name
- NCT01323959
- Testing
- BoostrixTM Polio
- Where
- 15 sites in France, Germany
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Polio, Poliomyelitis
Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine
The purpose of this study is to generate data to support the registration extension of IMOVAX Polio to be used in a sequential vaccination.
- Trial name
- NCT01475539
- Testing
- Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio, Live oral poliovirus type 1, 2 and 3
- Where
- China
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Measles Vaccination, Oral Polio Vaccine
Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children
The world is set on eradicating measles and polio infections in the coming decade. Once both infections are under control, campaigns with measles and oral polio vaccines will be phased out.
- Conditions
- Measles Vaccination, Oral Polio Vaccine, Non-specific/Heterologous Effects of Vaccines, Mortality
- Trial name
- RE-CAMP (NCT03460002)
- Testing
- Measles vaccine, Oral polio vaccine
- Where
- Guinea-Bissau
- Volunteers
- 28,612 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Poliomyelitis
Safety of Imovax Polio in Chinese Infants and Children
To describe the tolerance in terms of occurrence of serious adverse reactions and severe adverse reactions (injection site and systemic) within eight days after one dose of IMOVAX Polio™ administered in children and infants.
- Trial name
- NCT00258843
- Testing
- Inactivated Poliomyelitis vaccine
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis
Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants
The study will evaluate the safety and reactogenicity of Poliorix given as primary vaccination course to Chinese children at 2, 3 and 4 months of age.
- Trial name
- NCT00937404
- Testing
- Poliorix
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis Immunisation, Diphtheria Immunisation
Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand
Primary Objective: To demonstrate the non-inferiority of the SHAN6™ vaccine to the licensed SHAN5™ given with bOPV and IPV vaccines when coadministered with PCV and ORV Secondary Objective: To describe the immunogenicity profile…
- Conditions
- Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation, Hepatitis B Immunisation
- Trial name
- NCT04429295
- Testing
- DTwP-HepB-Hib-IPV hexavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b, inactivated poliovirus), DTwP-HepB-Hib pentavalent vaccine (Diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen (HBsAg), Haemophilus influenzae type b), Inactivated Poliomyelitis Vaccine
- Where
- 3 sites in Thailand
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acellular Pertussis, Tetanus
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488
Booster and immune memory study
- Conditions
- Acellular Pertussis, Tetanus, Hepatitis B, Diphtheria
- Trial name
- NCT00307567
- Testing
- Pneumococcal (vaccine)
- Where
- 51 sites in Germany
- Volunteers
- 689 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis
Safety and Immunogenicity of IPOVAC in Young Children
A dose escalating study with 3 different dosing regimens of the studied vaccine (IPOVAC- POLYVAC-Vietnam) and a licensed vaccine (IMOVAC-Sanofi Pasteur- France) is conducted in Vietnamese children, aged 2 months and above to…
- Trial name
- NCT02775942
- Testing
- IMOVAC-POLIO, IPOVAC 1.5:5:5, IPOVAC, 3:10:10
- Where
- 2 sites in Vietnam
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Institute of Hygiene and Epidemiology, Vietnam